The Christie NHS Foundation Trust’s penile cancer service had a strong presence at the European Association of Urology (EAU) Congress 2026 in London, sharing a wide range of work from across the service.

With 14 poster presentations, 2 educational sessions and a chaired session on rare male genital tumours, the team contributed to discussions on topics including HPV-related disease, tumour biology, and outcomes from a large single-centre patient group. They also presented work focusing on patient-reported outcomes after surgery, reflecting the importance of understanding patients’ experiences alongside clinical results.

Together, these contributions highlight the team’s ongoing work to improve care and outcomes for people affected by penile cancer.

The Christie urology team at EAU26

Session chair

  • Parnham A. Rare male Genital Tumours: Penile and Testis

Educational sessions

  • Parnham A. Premalignant lesions of the Penis and Scrotum; Male Genital Diseases
  • Parnham A. Penile Cancer Management of the Lymph Nodes
  • Oates J. Surgical Management of retroperitoneal sarcoma

Penile cancer

  • Lim X. The Heterogeneous Genomic Landscape of HPV-Positive Squamous Cell Carcinoma: An Analysis of 30 cases
  • Azhar F. Immune Checkpoint Status and The Tumour-Immune Microenvironment in Primary and Lymph Node Metastatic Penile Cancer
  • Tuffa NT. Survival Trends in HPV-independent and HPV-associated PSCC at a large single site centre: A retrospective analysis of 800 patients
  • Chowdhury M. Audit of ePROMs uptake and patient-reported outcomes following penectomy and nodal surgery

Adrenal surgery

  • Costa Silva A. Pushing boundaries in robotic adrenal surgery: the day-case ERAS experience.

Prostate cancer

  • Clarke N. Time to subsequent chemotherapy with capivasertib + abiraterone vs placebo + abi in patients with PTEN deficient mHSPC: CAPItello-281
  • Gray S. Skeletal muscle index as a prognostic and predictive biomarker in de novo hormone-sensitive prostate cancer: an exploratory analysis of four trials embedded within the STAMPEDE platform
  • Gray S. The impact of metformin on body composition in metastatic hormone-sensitive prostate cancer: exploratory analysis of the STAMPEDE metformin trial
  • El-Taji O. Identifying and predicting non-cancer mortality risk in mHSPC following doublet therapy in the STAMPEDE trial
  • Bristow RG. Tumour Evolution within patient-derived models of localised hereditary prostate cancer